Mankind Pharma has entered into a partnership with Innovent Biologics for licensing and commercialising Sintilimab for cancer in India.

AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs for Dermatomyositis have a 60% phase transition success ...

CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

CR-4056 is under clinical development by Rottapharm Biotech and currently in Phase II for Osteoarthritis Pain.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...